WO2009153428A3 - Utilisation du trilostane pour le traitement de la depression - Google Patents

Utilisation du trilostane pour le traitement de la depression Download PDF

Info

Publication number
WO2009153428A3
WO2009153428A3 PCT/FR2009/000576 FR2009000576W WO2009153428A3 WO 2009153428 A3 WO2009153428 A3 WO 2009153428A3 FR 2009000576 W FR2009000576 W FR 2009000576W WO 2009153428 A3 WO2009153428 A3 WO 2009153428A3
Authority
WO
WIPO (PCT)
Prior art keywords
trilostane
treating depression
antidepressant
potentiated
anxiolytic
Prior art date
Application number
PCT/FR2009/000576
Other languages
English (en)
Other versions
WO2009153428A2 (fr
Inventor
Claude Laruelle
Tangui Maurice
Julie Espallergues
Jamal Temsamani
Original Assignee
Cll Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cll Pharma filed Critical Cll Pharma
Publication of WO2009153428A2 publication Critical patent/WO2009153428A2/fr
Publication of WO2009153428A3 publication Critical patent/WO2009153428A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention se rapporte à des nouvelles indications thérapeutiques du trilostane ou d'un de ses dérivés, comme antidépresseur et comme anxiolytique. En particulier, l'invention montre que le trilostane a un effet antidépresseur potentialisé (accru) chez des patients atteints par la maladie d'Alzheimer. De plus, la population des personnes âgées est particulièrement visée par cette invention.
PCT/FR2009/000576 2008-05-27 2009-05-15 Utilisation du trilostane pour le traitement de la depression WO2009153428A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0802905A FR2931678B1 (fr) 2008-05-27 2008-05-27 Utilisation du trilistane pour le traitement de la depression
FR0802905 2008-05-27

Publications (2)

Publication Number Publication Date
WO2009153428A2 WO2009153428A2 (fr) 2009-12-23
WO2009153428A3 true WO2009153428A3 (fr) 2010-04-29

Family

ID=39865372

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2009/000576 WO2009153428A2 (fr) 2008-05-27 2009-05-15 Utilisation du trilostane pour le traitement de la depression

Country Status (2)

Country Link
FR (1) FR2931678B1 (fr)
WO (1) WO2009153428A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080930A1 (fr) * 2001-04-09 2002-10-17 Stegram Pharmaceuticals Limited Utilisation des derives de 2-alpha-cyano-4-alpha, 5-alpha-epoxyandrostan-17-beta-ol-3-one pour la reduction de niveaux de cortisol serique et pour le traitement de conditions cliniques associees
US20030232798A1 (en) * 2001-06-12 2003-12-18 Yadon Arad Adrenal enzyme inhibitors
WO2007009087A2 (fr) * 2005-07-12 2007-01-18 Dmi Biosciences, Inc. Procedes et produits de traitement de maladies
US20070078114A1 (en) * 2005-09-02 2007-04-05 Myriad Genetics, Incorporated Combination therapy for alzheimer's disease and other diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080930A1 (fr) * 2001-04-09 2002-10-17 Stegram Pharmaceuticals Limited Utilisation des derives de 2-alpha-cyano-4-alpha, 5-alpha-epoxyandrostan-17-beta-ol-3-one pour la reduction de niveaux de cortisol serique et pour le traitement de conditions cliniques associees
US20030232798A1 (en) * 2001-06-12 2003-12-18 Yadon Arad Adrenal enzyme inhibitors
WO2007009087A2 (fr) * 2005-07-12 2007-01-18 Dmi Biosciences, Inc. Procedes et produits de traitement de maladies
US20070078114A1 (en) * 2005-09-02 2007-04-05 Myriad Genetics, Incorporated Combination therapy for alzheimer's disease and other diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LONGONE ET AL: "The complex roles of neurosteroids in depression and anxiety disorders", NEUROCHEMISTRY INTERNATIONAL, PERGAMON PRESS, OXFORD, GB, vol. 52, no. 4-5, 28 January 2008 (2008-01-28), pages 596 - 601, XP022435352, ISSN: 0197-0186 *
ROBICHAUD M ET AL: "Modulation of the firing activity of female dorsal raphe nucleus serotonergic neurons by neuroactive steroids", JOURNAL OF ENDOCRINOLOGY 200407 GB, vol. 182, no. 1, July 2004 (2004-07-01), pages 11 - 21, XP002501547, ISSN: 0022-0795 *
YAMAMOTO T ET AL: "The effect of stress application on vestibular compensation", ACTA OTO-LARYNGOLOGICA 2000 NO, vol. 120, no. 4, 2000, pages 504 - 507, XP009107771, ISSN: 0001-6489 *

Also Published As

Publication number Publication date
FR2931678B1 (fr) 2010-10-01
WO2009153428A2 (fr) 2009-12-23
FR2931678A1 (fr) 2009-12-04

Similar Documents

Publication Publication Date Title
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
WO2009036175A3 (fr) Inhibiteur de f1f0-atpase et procédés associés
WO2010127099A3 (fr) Compositions pharmaceutiques comprenant de l'epa et un agent cardiovasculaire et leurs procédés d'utilisation
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
TR201819564T4 (tr) Cmt ve ilgili bozuklukların tedavisi için yeni terapötik yaklaşımlar.
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
EA201270480A1 (ru) Новые соединения
HK1146485A1 (fr)
WO2009126688A8 (fr) Compositions et procédés nouveaux pour le traitement de maladies de nature immunitaire
WO2009002423A3 (fr) Dérivés de guanine polycycliques et leurs procédés d'utilisation
MX350761B (es) Inhibidores de isoindolinona de fosfatidilinositol 3-cinasa.
NO20081527L (no) Anvendelse av flibanserin for behandling av pre-menopausal seksuell lyst forstyrrelser
WO2007084684A3 (fr) Utilisations therapeutiques d’inhibiteurs de rtp801
ATE416177T1 (de) Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer
WO2010083207A3 (fr) Inhibiteurs de la protéine kinase c et leurs utilisations
MY145349A (en) Benzofuro- and benzothienopyrimidine modulators of the histamine h4 receptor
WO2009099553A3 (fr) Utilisation d’inhibiteur de kinase pour le traitement de l’athérosclérose
WO2009136997A3 (fr) Inhibiteurs des cathepsines l, b et s humaines
WO2010129048A3 (fr) Composés thérapeutiques
WO2007022642A3 (fr) Molecules anti-inflammatoires et leurs utilisations
WO2009134668A3 (fr) Modulateurs allostériques positifs pour le récepteur m1 de 4-oxo-1,4-dihydroquinoléine
MX350145B (es) Extracto proteolitico a partir de bromelaina para el tratamiento de trastornos del tejido conectivo.
WO2011061700A3 (fr) Inhibiteurs ifnϒ pour le traitement de maladies des motoneurones
WO2009117283A3 (fr) Modulateurs allostériques positifs du récepteur m1 de la quinolizidine

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09765990

Country of ref document: EP

Kind code of ref document: A2